To enhance service speed and avoid tariff delays, we've opened a US warehouse. All US orders ship directly from our US facility.
| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC70865 | UHRF1 PHD inhibitor MLD4 Featured |
UHRF1 PHD inhibitor MLD4 is a specific compound that selectively inhibits the UHRF1-histone interaction (IC50=12.4 uM), targets the PHD finger of UHRF1, specifically disrupting histone H3 arginine 2 interactions with the PHD finger.UHRF1 PHD inhibitor MLD4 inhibited binding between H3K9me3(FAM) and UHRF1 with IC50 of 24-26 uM, displace UHRF1-histone H3 binding in cells.
More description
|
|
| DC70653 | NJH-2-075 Featured |
NJH-2-075 is an alkyne-functionalized probe of EN523, retains binding to OTUB1 in vitro.
More description
|
|
| DC70866 | UHRF1 PHD inhibitor MLD5 |
UHRF1 PHD inhibitor MLD5 is a specific compound that selectively inhibits the UHRF1-histone interaction (IC50=7.4 uM), targets the PHD finger of UHRF1, specifically disrupting histone H3 arginine 2 interactions with the PHD finger.UHRF1 PHD inhibitor MLD5 inhibited binding between H3K9me3(FAM) and UHRF1 with IC50 of 24-26 uM, displace UHRF1-histone H3 binding in cells.
More description
|
|
| DC65027 | 9H-Purin-6-amine, 2-chloro-N-[(4,6-dimethyl-3-pyridinyl)methyl]-9-(1-methylethyl)- Featured |
|
|
| DC65149 | CPD3236 Featured |
|
|
| DC65059 | 5-Methylsulfonyl-2-(2,2,2-trifluoro-1-Methylethoxy)benzoic acid Featured |
|
|
| DC60454 | BRD-K56819078 Featured |
BRD-K56819078 is a small-molecule senolytics and significantly decreases senescent cell burden and mRNA expression of senescence-associated genes in the kidneys of aged mices.
More description
|
|
| DC60456 | HHS-166 Featured |
HHS-166 shows dose-dependent inhibition of arsenite-induced stress granule (SG) formation, and liganded G3BP1 Y40 in the NTF2 dimerization domain of this essential nucleating protein for SG regulation.
More description
|
|
| DC60457 | AHL-030 Featured |
AHL-030 is a potent and selective EDC3-targeted ligands. AHL-030 is also an stress granules (SGs) enhancer and results in a 2-fold increase in SGs per arsenite-treated cell.
More description
|
|
| DC65238 | compound 53 Featured |
”Compound 53” (University of Texas Southwestern Medical Center) is a stimulator of interferon (IFN) genes (STING) agonist.
More description
|
|
| DC65240 | Compound 4e Featured |
“compound 4e” (Chiesi Farmaceutici) is an inhaled p38α/β mitogen-activated protein kinase (MAPK) inhibitor being developed for lung inflammatory diseases.
More description
|
|
| DC65256 | compound 6 Featured |
“Compound 6” (Novartis) is a first-in-class YAP-TEAD protein-protein inhibitor. The TEAD transcription factor and its coactivator YAP and WWTR1/TAZ of the Hippo pathway are responsible for directly regulating the expression of genes involved in cell proliferation and organ size.
More description
|
|
| DC65257 | compound 29 Featured |
Overcoming FGFR mutation resistance and FGFR1-mediated hyperphosphatemia toxicity through isoform-selective FGFR2/3 inhibition. “Compound 29” is an ATP-competitive fibroblast growth factor receptor (FGFR) 2/3 inhibitor with subnanomolar potency.
More description
|
|
| DC65252 | compound 27 Featured |
compound 27, is a potent (13 nM) CNS-penetrant compound that reduces very long chain fatty acid (VLCFA) levels in the CNS, which are believed to be pathological in the rare disease adrenoleukodystrophy (ALD). The starting point came from an HTS on compounds from an internal collection.
More description
|
|
| DC65253 | compound 14d Featured |
“Compound 14d” (Shionogi & Co.) is a highly potent, dose-dependent adenosine monophosphate activated protein kinase (AMPK) activator being investigated for its blood-glucose-lowering effects.
More description
|
|
| DC65266 | GLS-409 |
|
|
| DC65270 | DKR-1677 Featured |
|
|
| DC20649 | AKB-9778 Featured |
AKB-9778 is a potent, selective inhibitor of vascular endothelial protein tyrosine phosphatase (VE-PTP) with IC50 of 17 pM.
More description
|
|
| DC65273 | Compound 16 Featured |
|
|
| DC65275 | PFKFB3inhibitor(Compound69) Featured |
|
|
| DC65279 | NPD2381 Featured |
|
|
| DC20257 | KMN-159 Featured |
KMN-159 is a potent prostaglandin E2 type 4 (EP4) receptor agonist with Ki of 0.38 nM and shows five fold increase in potency versus KMN-80.
More description
|
|
| DC26194 | VU6003586 Featured |
VU6003586 is a novel allosteric modulators of mGlu5 with EC50 of 174 nM.
More description
|
|
| DC26190 | DS54360155 Featured |
DS54360155 is an orally potent analgesic without μ-opioid receptor agonist activity.
More description
|
|
| DC28065 | UCSF7447 Featured |
UCSF7447 is a selective and inverse agonists of melatonin receptor 1 (MT1) with EC50 of 41 nM, and shows 53-fold selectivity for human MT1 over human MT2.
More description
|
|
| DC28064 | UCSF3384 Featured |
UCSF3384 is a selective and inverse agonists of melatonin receptor 1 (MT1) with EC50 of 21 nM, and shows 31-fold selectivity for human MT1 over human MT2.
More description
|
|
| DC28066 | UCSF4226 Featured |
UCSF4226 is a selective and inverse agonists of melatonin receptor 1 (MT2) with EC50 of 6.3 nM, and shows 91-fold selectivity for human MT2 over human MT1.
More description
|
|
| DC53048 | HST5040 Featured |
HST5040 is a clinical candidate for the treatment of propionic acidemia (PA) and methylmalonic acidemia (MMA) with EC50 of 0.94 μM in P-CoA-lowering activity.
More description
|
|
| DC65341 | [18F]PSMA-1007 Featured |
[18F]PSMA-1007, a positron emission tomography (PET) tracer, specifically targets prostate-specific membrane antigen (PSMA), which is highly expressed in prostate cancer. PSMA-PET is effective especially for regional detection of biochemical recurrence, which significantly affects patient management. Herein, we established and optimized a one-step radiolabeling protocol to separate and purify [18F]PSMA-1007 with a CFN-MPS200 synthesizer for clinical application.
More description
|
|
| DC60481 | SC9 Featured |
SC9 is an uncompetitive inhibitor of WT dynamin-related protein 1 (Drp1) with IC50 of 270 nM. SC9 completely prevents the LPS-induced decline in cells with fused mitochondria.
More description
|
|